LHM Inc. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 138,451 shares of the company's stock, valued at approximately $9,727,000. Novo Nordisk A/S comprises about 3.2% of LHM Inc.'s investment portfolio, making the stock its 5th largest position.
Several other institutional investors have also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL boosted its holdings in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S during the first quarter worth $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the first quarter worth $30,000. 11.54% of the stock is owned by institutional investors.
Novo Nordisk A/S Price Performance
NVO stock traded up $1.12 during mid-day trading on Wednesday, hitting $50.90. The stock had a trading volume of 19,399,726 shares, compared to its average volume of 25,473,044. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $139.74. The firm has a market capitalization of $227.27 billion, a P/E ratio of 13.98, a P/E/G ratio of 1.71 and a beta of 0.63. The firm has a fifty day simple moving average of $65.84 and a 200 day simple moving average of $70.91.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.
Novo Nordisk A/S Cuts Dividend
The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 45.05%.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on NVO shares. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective on the stock in a research report on Wednesday. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of "Hold" and an average target price of $83.75.
Check Out Our Latest Stock Analysis on Novo Nordisk A/S
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access